Organization
Recordati Group
7 clinical trials
Clinical trial
A Double-blind Randomized Placebo-controlled Dose-finding Phase II Study to Assess the Efficacy and Safety of Pasireotide s.c. in Patients With Post-Bariatric HypoglycaemiaStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study)Status: Completed, Estimated PCD: 2023-07-10
Clinical trial
A Non-interventional Study to Assess the Long-term Safety and Efficacy of Osilodrostat in Patients With Endogenous Cushing's SyndromeStatus: Recruiting, Estimated PCD: 2028-06-01
Clinical trial
A Retrospective Observational Study to Evaluate the Safety and Effectiveness of Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome (LINC7)Status: Completed, Estimated PCD: 2023-09-30
Clinical trial
An Open-label, Multi-center, Roll-over Study to Assess Long Term Safety in Patients With Endogenous Cushing's Syndrome Who Have Completed a Prior Novartis-sponsored Osilodrostat (LCI699) Study and Are Judged by the Investigator to Benefit From Continued Treatment With OsilodrostatStatus: Completed, Estimated PCD: 2023-11-16
Clinical trial
An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide TreatmentStatus: Completed, Estimated PCD: 2023-07-29
Clinical trial
A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's DiseaseStatus: Recruiting, Estimated PCD: 2025-11-21